Off-Label Prosecutions Hinge On Patient Benefit, Government Attorneys Say
Executive Summary
Federal prosecutors say they will not pursue False Claims Act cases in which off-label use is the standard of care and note that the Caronia decision will have little impact on investigations; First Amendment defense fails in Par and Harkonen cases.
You may also be interested in...
FDA First Amendment Litigation: Will Amarin Case Break The Log Jam?
Courts have issued mixed rulings in cases challenging FDA restrictions on drug promotion, but with oral arguments set for July 7, Amarin’s suit could provide a definitive answer on what companies can tell physicians.
People In The News: New Top Management At Vivus, Merck Serono; Obama Nominates New ASPE at HHS
Vivus gets a new CEO and announces retirement of current president; Merck Serono announces a number of executive changes; Richard Frank is nominated to lead the Office of the Assistant Secretary of Evaluation and Planning at HHS; more personnel announcements in this month’s column.
Par’s Off-Label Plea Deal Includes Clawback For Execs’ Pay In Case Of Future Misconduct
Par will pay $45 million for off-label promotion of Megace ES and enter a corporate integrity agreement that restricts incentive compensation for sales reps; the firm also drops its suit against FDA and removes descriptions of conversations with government officials from its court filings.